Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
J07AL02	SYNFLORIX	B	Polysaccharide from each of 10 capsular types of pneumococcus (conjugated to carrier proteins) adsorbed onto aluminium phosphate - 1mcg/0.5ml, Polysaccharide of serotypes 41,2, 18C1,3 and 19F1,4 - 3mcg/0.5ml, 1 adsorbed onto aluminium phosphate - 0.5mg Al3+, 2 conjugated to protein D (derived from NTHi) carrier protein - ~ 13mcg, 3 conjugated to tetanos toxoid carrier protein - ~ 8mcg, 4 conjugated to diphteria toxoid carrier protein - ~ 5mcg		Injectable suspension	4,675,228 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	157,788,549 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	157,788,549 L.L
B05BB02	SOLUFLEX DEXTROSE 2.5% SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%, Glucose - 2.5%		Injectable solution	150,543 L.L
B05BB02	SOLUFLEX DEXTROSE 2.5% SODIUM CHLORIDE 0.45% INJECTION, USP	G	Sodium chloride - 0.45%, Glucose - 2.5%		Injectable solution	222,941 L.L
L04AC18	SKYRIZI	BioTech	Risankizumab - 150mg	150mg	Injectable solution	276,469,860 L.L
N02BE01	STOPALGIC	G	Paracetamol - 1g/100ml	1g/100ml	Injectable solution	1,536,012 L.L
N02BE01	SOLUFLEX PARACETAMOL	G	Paracetamol - 1g/100ml	1g/100ml	Injectable solution	211,175 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 90mg	90mg	Injectable solution	L.L
M03AC11	SISACURE	G	Cisatracurium (besylate) - 20mg/10ml	20mg/10ml	Injectable solution	1,408,347 L.L
N02BE01	SUPOFEN	G	Paracetamol - 10mg/ml	10mg/ml	Injectable solution	7,675,286 L.L
B05BC01	SERUFLEX MANNITOL 20% INJECTION, USP	G	Mannitol - 20g/100ml	20g/100ml	Injectable solution	402,213 L.L
B05BC01	SOLUFLEX MANNITOL 20% INJECTION, USP	G	Mannitol - 20g/100ml	20g/100ml	Injectable solution	603,320 L.L
N06BX06	SOMAZINA	B	Citicoline (sodium) - 1,000mg/4ml	1,000mg/4ml	Injectable solution	787,492 L.L
A10BJ02	SAXENDA	BioTech	Liraglutide - 6mg/ml	6mg/ml	Injectable solution	16,747,035 L.L
A10BJ06	SEMATIDE	G	Semaglutide - 1mg	1mg	Injectable solution	9,288,397 L.L
A10BJ06	SEMATIDE	G	Semaglutide - 0.25mg & 0.5mg		Injectable solution	9,288,397 L.L
H01CB03	SOMATULINE AUTOGEL	B	Lanreotide (acetate) - 120mg	120mg	Injectable solution	L.L
B05CX01	SOLUFLEX DEXTROSE 10% INJECTION, USP	G	Glucose - 10%	10%	Injectable solution	219,493 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	205,703 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	221,792 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	185,018 L.L
M05BA08	SIMPLA	G	Zoledronic acid - 5mg/100ml	5mg/100ml	Injectable solution	13,071,402 L.L
L04AC05	STELARA	BioTech	Ustekinumab - 45mg	45mg	Injectable solution	L.L

...